New Products In Brief
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific becomes the first with drug-eluting stents that are FDA-approved for use in patients experiencing a heart attack. More product news.
You may also be interested in...
Edwards Reveals Sapien Launch Plans For Transapical Delivery Method
Edwards estimates that the approximately 20%-30% of patients who would otherwise qualify but can’t receive a Sapien valve because their femoral artery is too small would likely make good candidates for the transapical, through the ribcage, route.
Research in Brief
Enrollment ends for Boston Sci’s latest Watchman trial; Edwards, MicroVention studies begin.
People In Brief
The latest moves by movers and shakers in the medical device and diagnostics industries.